This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-HER2/neu IgG to IL15. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the HER2/neu as well as the biological activity of IL15. The goal of this antibody-cytokine fusion protein to cancer therapy is to concentrate the cytokine in the tumor microenvironment and in so doing directly enhance the tumoricidal effect of the antibody and/or enhance the host immune response (T-cell, B-cell or NK) against the tumor. This immunocytokine was designed for treating HER-2/neu over-expressing cancer.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
IAB-B008(A) | Recombinant Anti-human ERBB2 Intrabody [(D-Arg)9] | IF, FC, FuncS | scFv-(D-Arg)9 |
IAB-B008(G) | Recombinant Anti-human ERBB2 Intrabody [+36 GFP] | WB, ICC, FuncS | scFv-(+36GFP) |
IAB-B008(T) | Recombinant Anti-human ERBB2 Intrabody [Tat] | ICC, Neut, FuncS | scFv-Tat |
There are currently no Customer reviews or questions for ACFP-SH010. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.